Feature - Ultragenyx_450x300
Thinking Differently About Rare Disease Therapies
As Ultragenyx continues building its new gene therapy manufacturing facility, CEO and president Dr. Emil Kakkis talks about his unique outlook on the rare disease space.  Continue Reading..
  • Who Are The “Right” People?
    4/1/2022

    It always will be important for business leaders to surround themselves with the right people. The thing to remember, however, is that there are many variables to determine who the “right” person is.

Ben Comer_2022_1

Ben Comer

Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.